Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]
Drug: ribavirin [Copegus]
Drug: Pioglitazone

First Posted Date: 2007-10-17

Last Posted Date: 2012-05-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 155

Registration Number: NCT00545233

BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis

Phase 4

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]

First Posted Date: 2007-10-17

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 585

Registration Number: NCT00545909

A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

Phase 4

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: Ibandronate

First Posted Date: 2007-10-17

Last Posted Date: 2016-10-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 716

Registration Number: NCT00545363

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

Phase 4

Completed

Conditions: Post Menopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]

First Posted Date: 2007-10-17

Last Posted Date: 2015-08-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 596

Registration Number: NCT00545480

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2007-10-17

Last Posted Date: 2019-01-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 86

Registration Number: NCT00545714

Locations: 🇪🇸
Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia, Zaragoza, Spain
🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇪🇸
Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain

and more 30 locations

ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Phase 4

Completed

Conditions: Post Menopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]

First Posted Date: 2007-10-17

Last Posted Date: 2016-11-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 561

Registration Number: NCT00545090

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin
Drug: Docetaxel
Drug: Pertuzumab

First Posted Date: 2007-10-17

Last Posted Date: 2017-08-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 417

Registration Number: NCT00545688

Locations: 🇦🇺
Geelong Hospital; Andrew Love Cancer Centre, Geelong, Victoria, Australia
🇲🇽
ARKE Estudios Clínicos S.A. de C.V., Mexico City, Mexico
🇮🇱
Meir Medical Center; Oncology, Kfar-Saba, Israel

and more 74 locations

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.

Phase 4

Completed

Conditions: Liver Transplantation

Interventions: Drug: Mycophenolate mofetil, adjusted dose
Drug: Corticosteroids, IV
Drug: Tacrolimus
Drug: Mycophenolate mofetil, Standard dose
Drug: Corticosteroids, PO

First Posted Date: 2007-10-17

Last Posted Date: 2014-07-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 180

Registration Number: NCT00545402

MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Methoxy polyethylene glycol-epoetin beta

First Posted Date: 2007-10-17

Last Posted Date: 2016-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 120

Registration Number: NCT00545571

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Placebo
Drug: Methotrexate

First Posted Date: 2007-09-26

Last Posted Date: 2017-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 132

Registration Number: NCT00535782

Locations: 🇺🇸
Rheumatology Associates of North Alabama, Huntsville, Alabama, United States
🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸
Arthritis & Rheumatism; Disease Specialities, Aventura, Florida, United States

and more 37 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy